Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling

BACKGROUND: Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor activation, the metabolically-inactive breakdown product, GLP-1(9–36)amide, also...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Emma, Tate, Mitchel, Lockhart, Samuel, McPeake, Claire, O’Neill, Karla M., Edgar, Kevin S., Calderwood, Danielle, Green, Brian D., McDermott, Barbara J., Grieve, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832495/
https://www.ncbi.nlm.nih.gov/pubmed/27079193
http://dx.doi.org/10.1186/s12933-016-0386-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832495/
https://www.ncbi.nlm.nih.gov/pubmed/27079193
http://dx.doi.org/10.1186/s12933-016-0386-5

Ejemplares similares